We are analyzing https://link.springer.com/article/10.1007/s002800051097.

Title:
Matrix metalloproteinases and metastasis | Cancer Chemotherapy and Pharmacology
Description:
Metastatic disease is responsible for the majority of cancer-related deaths, either directly due to tumor involvement of critical organs or indirectly due to complications of therapy to control tumor growth and spread. An understanding of the mechanisms of tumor cell invasion and metastasis may be important for devising therapies aimed at preventing tumor cell spread. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteinases whose enzymatic activity is directed against components of the extracellular matrix (ECM). In humans, 16 members of this family have been identified by cloning and sequencing. These proteinases are linked by a core of common domain structures and by their relationship to a family of proteinase inhibitors called the tissue inhibitors of metalloproteinases (TIMPs). Four members of the TIMP family have been cloned and sequenced in humans and they inhibit MMPs by forming tight-binding, noncovalent associations with the active site of the MMPs. MMPs facilitate tumor cell invasion and metastasis by at least three distinct mechanisms. First, proteinase action removes physical barriers to invasion through degradation of ECM macromolecules such as collagens, laminins, and proteoglycans. This has been demonstrated in vitro through the use of chemoinvasion assays and in vivo by the presence of active MMPs at the invasive front of tumors. Second, MMPs have the ability to modulate cell adhesion. For cells to move through the ECM, they must be able to form new cell–matrix and cell–cell attachments and break existing ones. Using a cell transfection system that altered the ratio of MMP-2 to TIMP-2 we have demonstrated significant variation in the adhesive phenotype of tumor cells. Finally, MMPs may act on ECM components or other proteins to uncover hidden biologic activities. For example, the angiogenesis inhibitor angiostatin may be produced from plasminogen by MMP action and laminin-5 is specifically degraded by MMP-2 to produce a soluble chemotactic fragment. Thus MMPs play multiple key roles in facilitating the metastasis of tumor cells. Therapies designed to interfere with specific MMP actions may be useful in the control of metastatic disease.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Mobile Technology & AI
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

article, matrix, mmps, metalloproteinases, tumor, metastasis, cancer, cell, privacy, cookies, content, publish, search, invasion, family, ecm, mmp, access, chapter, data, information, log, journal, research, kleiner, stetlerstevenson, cells, discover, springer, site, optional, personal, parties, policy, find, track, chemotherapy, pharmacology, cite, david, william, explore, metastatic, disease, due, control, spread, mechanisms, therapies, components,

Topics {✒️}

month download article/chapter tumor cell invasion stetler-stevenson rights privacy choices/manage cookies cell–cell attachments article cancer chemotherapy cancer-related deaths modulate cell adhesion cell transfection system proteinase inhibitors called full article pdf national cancer institute target matrix metalloproteinases european economic area zinc-dependent endoproteinases common domain structures forming tight-binding angiogenesis inhibitor angiostatin soluble chemotactic fragment epithelial-mesenchymal transition conditions privacy policy extracellular matrix remodeling control tumor growth devising therapies aimed related subjects accepting optional cookies pages s42–s51 demonstrated significant variation stetler-stevenson specific mmp actions journal finder publish cell–matrix check access instant access matrix metalloproteinases metastatic disease privacy policy personal data extracellular matrix tumor involvement books a cancer initiation article log mmp action tumor cells optional cookies manage preferences pharmacology aims invasion article kleiner

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Matrix metalloproteinases and metastasis
         description: Metastatic disease is responsible for the majority of cancer-related deaths, either directly due to tumor involvement of critical organs or indirectly due to complications of therapy to control tumor growth and spread. An understanding of the mechanisms of tumor cell invasion and metastasis may be important for devising therapies aimed at preventing tumor cell spread. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteinases whose enzymatic activity is directed against components of the extracellular matrix (ECM). In humans, 16 members of this family have been identified by cloning and sequencing. These proteinases are linked by a core of common domain structures and by their relationship to a family of proteinase inhibitors called the tissue inhibitors of metalloproteinases (TIMPs). Four members of the TIMP family have been cloned and sequenced in humans and they inhibit MMPs by forming tight-binding, noncovalent associations with the active site of the MMPs. MMPs facilitate tumor cell invasion and metastasis by at least three distinct mechanisms. First, proteinase action removes physical barriers to invasion through degradation of ECM macromolecules such as collagens, laminins, and proteoglycans. This has been demonstrated in vitro through the use of chemoinvasion assays and in vivo by the presence of active MMPs at the invasive front of tumors. Second, MMPs have the ability to modulate cell adhesion. For cells to move through the ECM, they must be able to form new cell–matrix and cell–cell attachments and break existing ones. Using a cell transfection system that altered the ratio of MMP-2 to TIMP-2 we have demonstrated significant variation in the adhesive phenotype of tumor cells. Finally, MMPs may act on ECM components or other proteins to uncover hidden biologic activities. For example, the angiogenesis inhibitor angiostatin may be produced from plasminogen by MMP action and laminin-5 is specifically degraded by MMP-2 to produce a soluble chemotactic fragment. Thus MMPs play multiple key roles in facilitating the metastasis of tumor cells. Therapies designed to interfere with specific MMP actions may be useful in the control of metastatic disease.
         datePublished:
         dateModified:
         pageStart:S42
         pageEnd:S51
         sameAs:https://doi.org/10.1007/s002800051097
         keywords:
            Key words Matrix metalloproteinases
            Metastasis
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:43
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:David E. Kleiner
               affiliation:
                     name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
                     address:
                        name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William G. Stetler-Stevenson
               affiliation:
                     name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
                     address:
                        name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Matrix metalloproteinases and metastasis
      description: Metastatic disease is responsible for the majority of cancer-related deaths, either directly due to tumor involvement of critical organs or indirectly due to complications of therapy to control tumor growth and spread. An understanding of the mechanisms of tumor cell invasion and metastasis may be important for devising therapies aimed at preventing tumor cell spread. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteinases whose enzymatic activity is directed against components of the extracellular matrix (ECM). In humans, 16 members of this family have been identified by cloning and sequencing. These proteinases are linked by a core of common domain structures and by their relationship to a family of proteinase inhibitors called the tissue inhibitors of metalloproteinases (TIMPs). Four members of the TIMP family have been cloned and sequenced in humans and they inhibit MMPs by forming tight-binding, noncovalent associations with the active site of the MMPs. MMPs facilitate tumor cell invasion and metastasis by at least three distinct mechanisms. First, proteinase action removes physical barriers to invasion through degradation of ECM macromolecules such as collagens, laminins, and proteoglycans. This has been demonstrated in vitro through the use of chemoinvasion assays and in vivo by the presence of active MMPs at the invasive front of tumors. Second, MMPs have the ability to modulate cell adhesion. For cells to move through the ECM, they must be able to form new cell–matrix and cell–cell attachments and break existing ones. Using a cell transfection system that altered the ratio of MMP-2 to TIMP-2 we have demonstrated significant variation in the adhesive phenotype of tumor cells. Finally, MMPs may act on ECM components or other proteins to uncover hidden biologic activities. For example, the angiogenesis inhibitor angiostatin may be produced from plasminogen by MMP action and laminin-5 is specifically degraded by MMP-2 to produce a soluble chemotactic fragment. Thus MMPs play multiple key roles in facilitating the metastasis of tumor cells. Therapies designed to interfere with specific MMP actions may be useful in the control of metastatic disease.
      datePublished:
      dateModified:
      pageStart:S42
      pageEnd:S51
      sameAs:https://doi.org/10.1007/s002800051097
      keywords:
         Key words Matrix metalloproteinases
         Metastasis
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:43
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:David E. Kleiner
            affiliation:
                  name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
                  address:
                     name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William G. Stetler-Stevenson
            affiliation:
                  name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
                  address:
                     name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:43
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
      address:
         name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
         type:PostalAddress
      name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
      address:
         name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:David E. Kleiner
      affiliation:
            name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
            address:
               name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
               type:PostalAddress
            type:Organization
      name:William G. Stetler-Stevenson
      affiliation:
            name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
            address:
               name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
      name:Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA, , US
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(27)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.96s.

LINK . SPRINGER . COM {}